What do systematic reviews say?

Ruxolitinib vs placebo

Ruxolitinib may leads to lower overall survival (number of deaths at compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.51 [0.27, 0.98]
  1 study · 309 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 1.2 [0.44, 3.28]
  1 study · 219 participants
  Low

Ruxolitinib vs best available therapy

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 96 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib may leads to higher reduction in spleen size Magnetic resonance imaging or computed… compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 41.78 [2.61, 669.75]
  1 study · 219 participants
  Low

Ruxolitinib vs placebo

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 309 participants
  GRADE not reported

Ruxolitinib vs placebo

Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 9.74 [2.32, 40.96]
  1 study · 306 participants
  Low

Ruxolitinib vs placebo

Ruxolitinib may leads to higher safety (AE, adverse drug reaction): neutropenia Grades 3 or 4… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 3.57 [1.02, 12.55]
  1 study · 306 participants
  Low

Ruxolitinib vs placebo

Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 8.82 [4.4, 17.69]
  1 study · 309 participants
  Low

Ruxolitinib vs placebo

Ruxolitinib may leads to higher reduction in spleen size Magnetic resonance imaging or computed… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 64.58 [9.08, 459.56]
  1 study · 309 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.7 [0.2, 2.47]
  1 study · 219 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in progression Free Survival (number of patients who had progression at compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.81 [0.47, 1.39]
  1 study · 219 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): anemia Grades 3 or 4 according… compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 1.35 [0.91, 1.99]
  1 study · 219 participants
  Low